Compare DexCom, Inc. (DXCM) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ON Holding AG — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while ON Holding AG trades at $38.57 (market cap $12.49B). The key difference: DexCom, Inc. is far larger — about 2.2× ON Holding AG's market cap, and DexCom, Inc. is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| DXCM | ONON | |
|---|---|---|
Market Cap | $28.06B | $12.49B |
Sector | Health | Technology |
52-Week High | $89.53 | $54.24 |
52-Week Low | $54.84 | $31.88 |
Enterprise Value | $27.03B | $11.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
ONON trades at $37.80, up 0.16% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.34, revenue of $3.01B in 2025, and improving margins. Analyst sentiment is bullish with 77% buy ratings and a $47.33 consensus price target, suggesting 25% upside. Recent news highlights innovation and expansion into luxury lifestyle markets.
Outlook remains positive driven by earnings momentum and margin expansion, but risks include premium valuation and competitive pressures. The stock offers growth potential if execution continues, though high P/E of 40.42 requires sustained profit growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
